PresentationPresentation KPT-9274 Inhibits Cellular NAD and Synergizes with Doxorubicin to Treat Dogs with Lymphoma PDF (972.54 KB) Read MorePresentation A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB and Non-GCB subtypes PDF (3.85 MB) Read MorePresentation Disruption of Nuclear Export with Selinexor or KPT-8602 Reduces Androgen Receptor Expression and Leads to Potent Anti-Tumor Activity in Preclinical Models of Androgen-Independent Prostate Cancer PDF (3.21 MB) Read MorePresentation p21 activated kinase 4 (pak4) as a novel therapeutic target for non-hodgkin’s lymphoma PDF (1.81 MB) Read MorePresentation Anti-tumor Activity of Palbociclib is Enhanced by Selinexor in Preclinical Models of HER2+ Breast Cancer PDF (1.33 MB) Read MorePresentation The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma PDF (1.26 MB) Read MorePresentation Novel role of XPO1 in regulating MicroRNAs related to pancreatic ductal adenocarcinoma invasion and metastasis PDF (2.61 MB) Read MorePresentation A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma PDF (922.01 KB) Read MorePresentation Selinexor in Combination with Bortezomib and Dexamethasone (SVd) Demonstrates Significant Activity in Patients with Refractory MM: Results of Phase I STOMP Trial (MCRN02) PDF (1.89 MB) Read MorePresentation A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia PDF (350.19 KB) Read More Previous 1 2 3 4 5 6 … 15 Next